• Je něco špatně v tomto záznamu ?

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

M. Futema, U. Ramaswami, L. Tichy, MP. Bogsrud, KB. Holven, J. Roeters van Lennep, A. Wiegman, OS. Descamps, A. De Leener, E. Fastre, M. Vrablik, T. Freiberger, H. Esterbauer, H. Dieplinger, S. Greber-Platzer, AM. Medeiros, M. Bourbon, V....

. 2021 ; 319 (-) : 108-117. [pub] 20210113

Jazyk angličtina Země Irsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019303

Grantová podpora
British Heart Foundation - United Kingdom

BACKGROUND AND AIMS: Familial hypercholesterolaemia (FH) is commonly caused by mutations in the LDLR, APOB or PCSK9 genes, with untreated mean low density lipoprotein-cholesterol (LDL-C) concentrations being elevated in APOB mutation carriers, even higher in LDLR mutation and highest in those with a PCSK9 mutation. Here we examine this in children with FH from Norway, UK, The Netherlands, Belgium, Czech Republic, Austria, Portugal and Greece. METHODS: Differences in characteristics and pre- and post-treatment lipid concentrations in those with different molecular causes were compared by standard statistical tests. RESULTS: Data were obtained from 2866 children, of whom 2531 (88%) carried a reported LDLR/APOB/PCSK9 variant. In all countries, the most common cause of FH was an LDLR mutation (79% of children, 297 different), but the prevalence of the APOB p.(Arg3527Gln) mutation varied significantly (ranging from 0% in Greece to 39% in Czech Republic, p < 2.2 × 10-16). The prevalence of a family history of premature CHD was significantly higher in children with an LDLR vs APOB mutation (16% vs 7% p=0.0005). Compared to the LDLR mutation group, mean (±SD) concentrations of pre-treatment LDL-C were significantly lower in those with an APOB mutation (n = 2260 vs n = 264, 4.96 (1.08)mmol/l vs 5.88 (1.41)mmol/l, p < 2.2 × 10-16) and lowest in those with a PCSK9 mutation (n = 7, 4.71 (1.22)mmol/l). CONCLUSIONS: The most common cause of FH in children from eight European countries was an LDLR mutation, with the prevalence of the APOB p.(Arg3527Gln) mutation varying significantly across countries. In children, LDLR-FH is associated with higher concentrations of LDL-C and family history of CHD compared to those with APOB-FH.

1st Department of Pediatrics National and Kapodistrian University of Athens and Department of Inborn Errors of Metabolism and Inherited Dyslipidemias MITERA Children's Hospital Athens Greece

1st Department of Pediatrics National and Kapodistrian University of Athens Greece

3rd Department of Internal Medicine General University Hospital and 1st Faculty of Medicine Charles University U Nemocnice 1 Prague 2 128 08 Czech Republic

Cardiovascular Research Group Research and Development Unit Department of Health Promotion and Chronic Diseases National Institute of Health Doutor Ricardo Jorge Lisbon Portugal and University of Lisboa Faculty of Sciences BioISI Biosystems and Integrative Sciences Institute Lisboa Portugal

Centre de Génétique Humaine UCL Cliniques Universitaires Saint Luc Bruxelles Belgium

Centre for Cardiovascular Genetics Institute for Cardiovascular Science University College London London United Kingdom

Centre for Cardiovascular Surgery and Transplantation Czech Republic and Medical Faculty Masaryk University Pekarska 53 656 91 Brno Brno Czech Republic

Centre for Heart Muscle Disease Institute for Cardiovascular Science University College London London United Kingdom

Centre of Molecular Biology and Gene Therapy University Hospital Brno Brno Czech Republic

Centres Hospitaliers Jolimont Lipid Clinic Haine Saint Paul Belgium

Department of Laboratory Medicine Medical University of Vienna Vienna Austria

Department of Nutrition University of Oslo Oslo Norway

Department of Pediatrics Amsterdam University Medical Centers Amsterdam the Netherlands

Departments of Cardiology and Internal Medicine Erasmus Medical Center Rotterdam the Netherlands

Division of Pediatric Pulmonology Allergology and Endocrinology Department of Pediatrics and Adolescent Medicine Comprehensive Center Pediatrics Medical University Vienna Austria

Institute of Genetic Epidemiology Department of Genetics and Pharmacology Medical University of Innsbruck Schöpfstraße 41 6020 Innsbruck Austria

Lysosomal Disorders Unit Royal Free Hospital London United Kingdom

National Advisory Unit on Familial Hypercholesterolemia Department of Endocrinology Morbid Obesity and Preventive Medicine Oslo University Hospital Oslo Norway

Unit for Cardiac and Cardiovascular Genetics Department of Medical Genetics Oslo University Hospital Oslo Norway

000      
00000naa a2200000 a 4500
001      
bmc21019303
003      
CZ-PrNML
005      
20210830100857.0
007      
ta
008      
210728s2021 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.atherosclerosis.2021.01.008 $2 doi
035    __
$a (PubMed)33508743
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Futema, Marta $u Centre for Heart Muscle Disease, Institute for Cardiovascular Science, University College London, London, United Kingdom
245    10
$a Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries / $c M. Futema, U. Ramaswami, L. Tichy, MP. Bogsrud, KB. Holven, J. Roeters van Lennep, A. Wiegman, OS. Descamps, A. De Leener, E. Fastre, M. Vrablik, T. Freiberger, H. Esterbauer, H. Dieplinger, S. Greber-Platzer, AM. Medeiros, M. Bourbon, V. Mollaki, E. Drogari, SE. Humphries
520    9_
$a BACKGROUND AND AIMS: Familial hypercholesterolaemia (FH) is commonly caused by mutations in the LDLR, APOB or PCSK9 genes, with untreated mean low density lipoprotein-cholesterol (LDL-C) concentrations being elevated in APOB mutation carriers, even higher in LDLR mutation and highest in those with a PCSK9 mutation. Here we examine this in children with FH from Norway, UK, The Netherlands, Belgium, Czech Republic, Austria, Portugal and Greece. METHODS: Differences in characteristics and pre- and post-treatment lipid concentrations in those with different molecular causes were compared by standard statistical tests. RESULTS: Data were obtained from 2866 children, of whom 2531 (88%) carried a reported LDLR/APOB/PCSK9 variant. In all countries, the most common cause of FH was an LDLR mutation (79% of children, 297 different), but the prevalence of the APOB p.(Arg3527Gln) mutation varied significantly (ranging from 0% in Greece to 39% in Czech Republic, p < 2.2 × 10-16). The prevalence of a family history of premature CHD was significantly higher in children with an LDLR vs APOB mutation (16% vs 7% p=0.0005). Compared to the LDLR mutation group, mean (±SD) concentrations of pre-treatment LDL-C were significantly lower in those with an APOB mutation (n = 2260 vs n = 264, 4.96 (1.08)mmol/l vs 5.88 (1.41)mmol/l, p < 2.2 × 10-16) and lowest in those with a PCSK9 mutation (n = 7, 4.71 (1.22)mmol/l). CONCLUSIONS: The most common cause of FH in children from eight European countries was an LDLR mutation, with the prevalence of the APOB p.(Arg3527Gln) mutation varying significantly across countries. In children, LDLR-FH is associated with higher concentrations of LDL-C and family history of CHD compared to those with APOB-FH.
650    _2
$a dítě $7 D002648
650    _2
$a mutační analýza DNA $7 D004252
650    _2
$a lidé $7 D006801
650    12
$a hyperlipoproteinemie typ II $x diagnóza $x epidemiologie $x genetika $7 D006938
650    _2
$a lipidy $7 D008055
650    _2
$a mutace $7 D009154
650    12
$a proproteinkonvertasa subtilisin/kexin typu 9 $x genetika $7 D000071449
650    _2
$a receptory LDL $x genetika $7 D011973
651    _2
$a Rakousko $7 D001317
651    _2
$a Belgie $7 D001530
651    _2
$a Česká republika $x epidemiologie $7 D018153
651    _2
$a Evropa $7 D005060
651    _2
$a Řecko $7 D006115
651    _2
$a Nizozemsko $x epidemiologie $7 D009426
651    _2
$a Norsko $7 D009664
651    _2
$a Portugalsko $7 D011174
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ramaswami, Uma $u Lysosomal Disorders Unit, Royal Free Hospital, London, United Kingdom
700    1_
$a Tichy, Lukas $u Centre of Molecular Biology and Gene Therapy, University Hospital Brno, Brno, Czech Republic
700    1_
$a Bogsrud, Martin P $u National Advisory Unit on Familial Hypercholesterolemia, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway; Unit for Cardiac and Cardiovascular Genetics, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
700    1_
$a Holven, Kirsten B $u Department of Nutrition, University of Oslo, Oslo, Norway
700    1_
$a Roeters van Lennep, Jeanine $u Departments of Cardiology and Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
700    1_
$a Wiegman, Albert $u Department of Pediatrics, Amsterdam University Medical Centers, Amsterdam, the Netherlands
700    1_
$a Descamps, Olivier S $u Centres Hospitaliers Jolimont, Lipid Clinic, Haine-Saint-Paul, Belgium
700    1_
$a De Leener, Anne $u Centre de Génétique Humaine, UCL Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
700    1_
$a Fastre, Elodie $u Centre de Génétique Humaine, UCL Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
700    1_
$a Vrablik, Michal $u Third Department of Internal Medicine, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 1, Prague 2, 128 08, Czech Republic
700    1_
$a Freiberger, Tomas $u Centre for Cardiovascular Surgery and Transplantation, Czech Republic, and Medical Faculty, Masaryk University, Pekarska 53, 656 91 Brno, Brno, Czech Republic
700    1_
$a Esterbauer, Harald $u Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
700    1_
$a Dieplinger, Hans $u Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstraße 41, 6020, Innsbruck, Austria
700    1_
$a Greber-Platzer, Susanne $u Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center Pediatrics, Medical University Vienna, Austria
700    1_
$a Medeiros, Ana M $u Cardiovascular Research Group, Research and Development Unit, Department of Health Promotion and Chronic Diseases, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal and University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Lisboa, Portugal
700    1_
$a Bourbon, Mafalda $u Cardiovascular Research Group, Research and Development Unit, Department of Health Promotion and Chronic Diseases, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal and University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Lisboa, Portugal
700    1_
$a Mollaki, Vasiliki $u First Department of Pediatrics, National and Kapodistrian University of Athens, Greece
700    1_
$a Drogari, Euridiki $u First Department of Pediatrics, National and Kapodistrian University of Athens and Department of Inborn Errors of Metabolism and Inherited Dyslipidemias, "MITERA" Children's Hospital, Athens, Greece
700    1_
$a Humphries, Steve E $u Centre for Cardiovascular Genetics, Institute for Cardiovascular Science, University College London, London, United Kingdom. Electronic address: steve.humphries@ucl.ac.uk
773    0_
$w MED00009284 $t Atherosclerosis $x 1879-1484 $g Roč. 319, č. - (2021), s. 108-117
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33508743 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100857 $b ABA008
999    __
$a ok $b bmc $g 1690188 $s 1139749
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 319 $c - $d 108-117 $e 20210113 $i 1879-1484 $m Atherosclerosis $n Atherosclerosis $x MED00009284
GRA    __
$p British Heart Foundation $2 United Kingdom
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...